mRNA Synthesis Raw Materials Market Size, Share & Trends Analysis Report By Type (Capping Agents, Nucleotides, Plasmid DNA, Enzymes, Others), By Application (Vaccine Production, Therapeutics Production, Others), By End-user (Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs, Academic & Research Institutes), By Region, and Segment Forecasts, 2025-2034

Global mRNA Synthesis Raw Materials Market Size is valued at USD 1.8 Bn in 2024 and is predicted to reach USD 3.4 Bn by the year 2034 at a 6.6% CAGR during the forecast period for 2025-2034.

Key Industry Insights & Findings from the Report:

• Leading pharmaceutical companies new product introductions that improve service quality, rising service standards, and increased facility personalization are driving the RNA synthesis raw material market.
• A greater understanding of the significance of early detection and treatment of chronic diseases among the general public and healthcare professionals is anticipated to fuel market growth.
• North America dominated the market and accounted for a revenue share of global revenue in 2024.
• Expanding mRNA synthesis of raw materials is hindered by a lack of flexible, durable, and cost-effective manufacturing procedures. 

The mRNA synthesis raw material market revolves around the essential ingredients needed to produce messenger RNA (mRNA). Significant raw materials include nucleotides (the building blocks), enzymes (which help construct the mRNA), capping agents (that protect the message), and modified bases (to enhance performance). This market study encompasses companies that manufacture and supply these materials to biotech firms, pharmaceutical manufacturers, and research laboratories.

mRNA vaccines are more efficacious, have better immunogenicity, and cost less to produce than traditional treatments. For the projection period, mRNA synthesis and production services are anticipated to have rapid market expansion due to ongoing breakthroughs and advancements. Due to the key market players' goal of providing superior quality and efficacy products, there is an increasing demand for high-quality raw materials for efficient mRNA synthesis. This is essential for developing safe and effective pharmaceutical goods, vaccines, and medications. Key competitors' alliances, acquisitions, and partnerships to increase the supply of raw materials also drive the industry. The market is expanding due to new pharmaceutical companies' inventions, improved medical technology, and greater customization of facilities and services with higher quality and effectiveness.

Competitive Landscape

Some major key players in the mRNA Synthesis Raw Materials Market are:

• Roche
• Thermo Fisher Scientific Inc
• Creative Enzymes
• Promega Corporation
• Merck
• BOC Sciences
• Jena Bioscience GmbH
• Aldevron
• Sichuan Qingmu Pharmaceutical Co., Ltd
• TriLink BioTechnologies
• Creative Biogene
• New England Biolabs

Other Prominent Players

• Bio-Synthesis Inc.
• Integrated DNA Technologies (IDT)
• GenScript Biotech Corporation
• Yeasen Biotechnology (Shanghai) Co., Ltd.
• Eurogentec
• Beijing SBS Genetech Co., Ltd.
• Lucigen (LGC Biosearch Technologies)
• BioCat GmbH
• ATDBio Ltd.
• Bio Basic Inc.
• Sartorius AG
• HONGENE
• ArcticZymes Technologies

Market Segmentation:

The mRNA synthesis raw materials market is segmented into type, application, and end-user. Based on type, the market is segmented into capping agents, nucleotides, plasmid DNA, enzymes, and others. Based on the application, the market is divided into vaccine production, therapeutics production, and others. Based on the End-user, the market is divided into biopharmaceutical and pharmaceutical companies, cross and CMOS, and academic and research institutes.

The Capping Agents Segment is Expected to Have the Highest Growth Rate During the Forecast Period

Based on type, the market is segmented into capping agents, nucleotides, plasmid DNA, enzymes, and others. Among these, the capping agents’ segment is expected to have the highest growth rate during the forecast period. Capping agents are critical for mRNA stability, translation efficiency, and reduced immunogenicity, making them essential components in the synthesis of functional, therapeutic-grade mRNA. They play a vital role in the formation of the 5' cap structure, which is crucial for effective mRNA translation. The demand for capping agents has grown significantly with the expanding use of mRNA technologies in vaccines, gene therapies, and personalized medicines. This segment is further driven by innovations in cap analogs and enzymatic capping kits, which enhance the efficiency and safety of mRNA products. In comparison, nucleotides including modified variants like N1-methyl-pseudouridine are also used in large volumes but have a relatively lower unit cost, making their overall market share smaller despite their importance in mRNA synthesis.

The Vaccine Production Segment Dominates the Market

Based on the application, the market is divided into vaccine production, therapeutics production, and others. Among these, the vaccine production segment dominates the market. Vaccine production is the major demand driver in the mRNA synthesis raw materials market, especially in the post-COVID-19 era. The success of mRNA-based vaccines during the pandemic has accelerated research and development efforts, leading to a strong pipeline of mRNA vaccines targeting infectious diseases such as influenza, RSV, and HIV. This segment continues to be supported by government funding and global health initiatives aimed at pandemic preparedness and public health. While therapeutics production is rapidly growing, it remains an emerging segment, primarily focused on oncology, rare diseases, and genetic disorders. Although its current volume is smaller compared to vaccines, it holds significant growth potential due to increasing investments and clinical advancements.

North America Has the Largest Market Share During the Forecast Period.

North America is home to leading biotech and pharmaceutical companies, making it a major hub for the consumption and production of mRNA synthesis raw materials. The region boasts a well-established research ecosystem supported by top universities, advanced research institutes, and substantial funding from both public agencies, such as the NIH and BARDA, as well as private investors. Additionally, strong regulatory support for mRNA technologies through mechanisms like FDA fast-tracks and Emergency Use Authorizations has accelerated development timelines and market access. Combined with significant investments in pandemic preparedness and biotechnology innovation, these factors have firmly positioned North America as the dominant region in the mRNA synthesis raw materials market.

Recent Developments

• In Nov 2021, BOC RNA declared the growth of its oligo synthesis services with the intention of catering to a more diverse clientele within the biomedical sector.    In addition to natural DNA, siRNA, mRNA, and DNA/RNA oligos, BOC RNA offered a variety of oligonucleotides and derivative synthesis services, including non-natural and more stable oligonucleotides (cGMP grade and non-cGMP grade).

• In Sept 2022, Thermo Fisher Scientific introduced scalable mRNA production solutions utilizing customized Dynabeads. Utilizing Streptavidin for In Vitro Transcription and Carboxylic Acid for RNA Purification by Dynabeads enabled scalable, GMP-grade mRNA synthesis and purification for vaccine research and production. The Thermo ScientificTM TheraPureTM GMP portfolio of nucleotides and enzymes facilitated the workflow by providing solutions suitable for their intended use. It assisted mRNA companies in advancing more rapidly from development to commercialization.

mRNA Synthesis Raw Materials Market Report Scope :